{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:08:45Z","timestamp":1781845725730,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260598"],"award-info":[{"award-number":["82260598"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The combination of disitamab vedotin (RC48) with PD-1 inhibitors has shown synergistic potential in preclinical studies for treating advanced urothelial carcinoma (UC). Nevertheless, real-world evidence regarding its clinical efficacy and safety profile remains limited. This multicenter real-world study aims to comprehensively evaluate the therapeutic outcomes and safety of RC48 combined with PD-1 inhibitors in patients with locally advanced or metastatic urothelial carcinoma (La\/mUC), with a particular focus on analyzing the impact of comorbidities on treatment efficacy and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 132 patients with La\/mUC who received RC48 combined with a PD-1 inhibitor at six treatment centers between June 2022 and March 2024. Clinical\u2013pathological characteristics, treatment regimens, and follow-up data were collected from electronic medical record systems. Efficacy outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR). Safety was assessed by recording treatment-related adverse events (TRAEs), with efficacy evaluated across different disease subpopulations. Survival curves were generated using the Kaplan\u2013Meier method, and Cox proportional hazards regression was employed for survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 132 patients with La\/mUC were enrolled. The RC48 plus PD-1 inhibitor regimen demonstrated an ORR of 71.21% (95% CI: 62.97%\u201378.25%) and a DCR of 88.64% (95% CI: 82.10%\u201392.99%). The median PFS was 21 months (95% CI: 14\u201324 months), and the median OS was not reached. Kaplan\u2013Meier analyses indicated that comorbid conditions such as hypertension, diabetes, hyperlipidemia, or renal insufficiency did not compromise efficacy, with similar PFS and OS observed across subgroups. The most common TRAEs were fatigue (38.64%), nausea (35.61%), anemia (32.58%), pruritus (28.79%), and peripheral neuropathy (23.48%). The incidence of grade 3 adverse events was 13.64%, with no grade 4 or higher events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The RC48 plus PD-1 inhibitor treatment regimen demonstrated clear antitumor activity and manageable safety in a multicenter real-world study of patients with La\/mUC, with consistent therapeutic effects observed in patients with comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1815591","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:07:09Z","timestamp":1777442829000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xin Chang","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Urology, Second Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Jiangxi Provincial People\u2019s Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Yang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Urology, First Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, First People\u2019s Hospital of Jiujiang City","place":["Jiujiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Biao","family":"Huang","sequence":"additional","affiliation":[{"name":"Jiangxi Cancer Hospital and Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: A systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae215","article-title":"Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma","volume":"29","author":"Zhang","year":"2024","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234078","article-title":"Evolving treatment landscape of frontline therapy for metastatic urothelial carcinoma: Current insights and future perspectives","volume":"16","author":"Kwon","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105067","article-title":"Antibody-drug conjugates in urothelial, prostate, and renal cell cancers: A review of current and emerging therapies","volume":"218","author":"Perera","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/medicina62010046","article-title":"A review of the latest evidence on prognostic factors in locally advanced and metastatic urothelial carcinoma treated with immune checkpoint inhibitors","volume":"62","author":"Cojocaru","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.02.009","article-title":"Impact of immune checkpoint inhibitors as neoadjuvant therapy for muscle-invasive bladder cancer: A systematic review, meta-analysis, and network meta-analysis","volume":"8","author":"Matsukawa","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01165-1","article-title":"HER2-positive urothelial carcinoma: Current evidence on targeted agents and immunotherapy-based combinations","volume":"20","author":"Ciciriello","year":"2025","journal-title":"Target Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978266","article-title":"Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): A phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2026.01.027","article-title":"Contextualizing the development of anti-HER2 therapies for patients with advanced urothelial carcinoma","author":"Maiorano","year":"2026","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/17562872241249073","article-title":"Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer","volume":"16","author":"Domb","year":"2024","journal-title":"Ther Adv Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.06.006","article-title":"Antibody-drug conjugates for urothelial carcinoma","volume":"41","author":"Thomas","year":"2023","journal-title":"Urol Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12894-025-01960-y","article-title":"Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Urol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01075-x","article-title":"HER2 and urothelial carcinoma: Current understanding and future directions","volume":"23","author":"Raggi","year":"2026","journal-title":"Nat Rev Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2535280","article-title":"SGNDV-001: Disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00345-025-05544-1","article-title":"Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma","volume":"43","author":"Yao","year":"2025","journal-title":"World J Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100637","article-title":"Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study","volume":"6","author":"Yan","year":"2025","journal-title":"Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01211-1","article-title":"Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: A multicenter real-world study","volume":"10","author":"Guo","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13903","article-title":"Outcomes of avelumab treatment in advanced urothelial carcinoma according to age, performance status, and timing","volume":"39","author":"Furubayashi","year":"2025","journal-title":"In Vivo"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.79002","article-title":"Recent advances in immunotherapy for bladder cancer treatment","volume":"17","author":"Alqarni","year":"2025","journal-title":"Cureus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2342227","article-title":"Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy","volume":"20","author":"T O\u2019Dwyer","year":"2024","journal-title":"Future Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12894-025-01754-2","article-title":"Impact of concomitant medications on the oncologic efficacy of systemic therapy in patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis","volume":"25","author":"Tsuboi","year":"2025","journal-title":"BMC Urol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12967-025-06237-4","article-title":"The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: A multicenter, real-world study","volume":"23","author":"Ge","year":"2025","journal-title":"J Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2025.100692","article-title":"Patients\u2019 perspectives and experiences regarding medication reviews: A cross-sectional survey study","volume":"21","author":"Falke","year":"2025","journal-title":"Explor Res Clin Soc Pharm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815591\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:07:10Z","timestamp":1777442830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815591\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1815591"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1815591","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1815591"}}